PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Eastern Biotech & Life Sciences FZ-LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Eastern Biotech to Promote deCODE Genetics’ DNA-based Tests for Assessing Risk of Diabetes and Other - Eastern Biotech to promote deCODE genetics’ DNA-based tests for assessing risk of diabetes and other Predictive Test
Eastern Biotech to Promote deCODE Genetics’ DNA-based Tests for Assessing Risk of Diabetes and Other

 

NewswireToday - /newswire/ - Dubai, UAE, United Arab Emirates, 2008/10/16 - Eastern Biotech to promote deCODE genetics’ DNA-based tests for assessing risk of diabetes and other Predictive Test.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Eastern Biotech is pleased to announce its partnership with deCODE genetics to market deCODE’s tests for genetic variants conferring risk of a number of common diseases. The partnership allows Eastern Biotech to offer its clients access to new genetic tests for assessing individual risk of type 2 diabetes mellitus, myocardial infarction, atrial fibrillation, prostate cancer, glaucoma, breast cancer and others that deCODE is developing. All deCODE tests have been validated through clinical trials involving thousands of patients and controls from multiple populations, and have received full regulatory approval. Eastern Biotech aims to become a leading provider of deCODE tests in the UAE and other Middle Eastern Countries.

In the past, Eastern Biotech has introduced to the Middle East products such as CancerSafe, genomic profile tests, family ancestry and other DNA tests. This new range of deCODE genetics tests from type 2 diabetes to common cancers add a whole new dimension to its current range of Predictive Genetic tests.

"Eastern Biotech is committed to provide advanced healthcare solutions to the region" said Dr. Sanjida Ahmed, Director of Research at Eastern Biotech. "We are constantly on the search for new breakthroughs and we are proud of our collaboration with deCODE. We are very excited to be offering this new and growing product range, which is going to be very useful for the UAE and Middle East populations.” She added.

Pankaj Sohaney, Manager Marketing said "The demand for genetic testing services in the region is increasing. We receive regular enquiries from all GCC countries. This partnership ensures that we are able to provide our customers with the widest range of high quality genetic tests."

Genetic testing is becoming an increasingly important component of modern healthcare as the focus shifts from intervention to prevention. An awareness of clinical predisposition to the development of disease provides us critical lead time for the implementation of vital pre-emptive and precautionary measures such as dietary factors, detailed screening or pharmaceutical intervention. Eastern Biotech’s agreement with deCODE ensures that local clinicians can provide their patients with the most accurate and timely information to delay or prevent the onset of diseases such as diabetes, heart disease and certain cancers.

About Eastern Biotech & Life Sciences
Eastern Biotech & Life Sciences (easternbiotech.com) is established within DuBiotech, the biotechnology park in Dubai since November 2005. Its vision is to promote the health of the people of the United Arab Emirates and the region through the introduction of biotechnological products and systems, and through research into the diseases relevant to this region, especially Genetic Disorders, Obesity, Diabetes and Heart disease.
Eastern Biotech is working as a clinical reference laboratory for various genetic and cytogenetic testing services in Middle East region through their test centers. Eastern Biotech is a pioneer in this region for online predictive genetic services, and has seen tremendous growth in the last 2 years.

About deCODE
deCODE is a biopharmaceutical company applying its discoveries in human genetics and its capabilities in chemistry and structural biology to the development of drugs and diagnostics for common diseases. deCODE’s therapeutics programs include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer’s disease and other conditions. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2™ for type 2 diabetes; deCODE AF™ for atrial fibrillation and stroke; deCODE MI™ for heart attack; deCODE ProCa™ for prostate cancer; deCODE Glaucoma™ for a major type of glaucoma; and deCODE BreastCancer™ for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics.SM for our pioneering personal genome analysis service, integrating the genetic variants included in these tests and those linked to another twenty common diseases.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Eastern Biotech & Life Sciences FZ-LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Eastern Biotech to Promote deCODE Genetics’ DNA-based Tests for Assessing Risk of Diabetes and Other

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Pankaj Sohaney - EasternBiotech.com  
+971 4 3692061 pankaj[.]easternbiotech.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Eastern Biotech & Life Sciences FZ-LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Eastern Biotech & Life Sciences FZ-LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)